Who makes UGT1A1 victim drug?

UGT1A1 victim drug is developed by Kadmon, a Sanofi Company.

What development phase is UGT1A1 victim drug in?

UGT1A1 victim drug is in Phase 1.

Last reviewed 2026-04-19 · How we verify

UGT1A1 victim drug

Kadmon, a Sanofi Company · Phase 1 active Small molecule

At a glance

Generic name	UGT1A1 victim drug
Sponsor	Kadmon, a Sanofi Company
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

UGT1A1 victim drug CI brief — competitive landscape report
UGT1A1 victim drug updates RSS · CI watch RSS
Kadmon, a Sanofi Company portfolio CI